Pancreatic Cancer Research

ResearcherFujian Medical UniversityActive in the last 2 years

Baiyong Shen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-3994-248X; OpenAlex author ID A5040580201, A5108864695. Sources: OpenAlex.

Their work

Papers
95 (first author 3, last author 49)
Trials
0
Grants
0
Labs led
1
Collaborators
178
Papers, trials and grants by year

2012: 1 paper · 2013: 4 papers · 2014: 3 papers · 2015: 3 papers · 2016: 5 papers · 2017: 4 papers · 2018: 4 papers · 2019: 10 papers · 2020: 5 papers · 2021: 13 papers · 2022: 9 papers · 2023: 16 papers · 2024: 7 papers · 2025: 7 papers · 2026: 4 papers

Papers 50 of 95

  1. Prognostic and predictive values of transcriptomic signatures in metastatic pancreatic cancer: A biomarker analysis of three French multicenter prospective ran… Co-author DOI 10.1016/j.canlet.2026.218745↗
  2. Longitudinal analysis of circulating tumor DNA and CA19-9 dynamics in predicting disease relapse and monitoring treatment response in stage I-III pancreatic du… Co-author DOI 10.1016/j.ejca.2026.117042↗
  3. Nimotuzumab Plus Gemcitabine-based Adjuvant Chemotherapy for Resectable Pancreatic Cancer: A Retrospective Observational Study. Co-author DOI 10.1097/mpa.0000000000002511↗
  4. FNDC4 Drives Metastasis and Immune Evasion in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-25-1001↗
  5. H19 promotes polarization and alternative splicing in tumor-associated macrophages, facilitating pancreatic cancer progression. Last author DOI 10.1016/j.canlet.2024.217389↗
  6. CEMIP2 sensitizes PDAC to chemotherapy through extracellular matrix remodeling by hyaluronan degradation. Co-author DOI 10.1016/j.canlet.2025.217898↗
  7. Tumor-associated Schwann cell remodeling under metabolic stress via lactate sensing orchestrates pancreatic ductal adenocarcinoma development. Last author DOI 10.1016/j.cmet.2025.07.008↗
  8. CTCF enhances pancreatic cancer progression via FLG-AS1-dependent epigenetic regulation and macrophage polarization. Last author DOI 10.1038/s41418-024-01423-1↗
  9. OFD1 inhibition induces BRCAness to create a therapeutic vulnerability to PARP inhibition in pancreatic cancer. Co-author DOI 10.1038/s41467-025-62295-8↗
  10. A clinically validated 3D deep learning approach for quantifying vascular invasion in pancreatic cancer. Co-author DOI 10.1038/s41746-025-02260-3↗
  11. The association between nutritional risk and survival time among patients with pancreatic cancer following pancreaticoduodenectomy: a retrospective cohort stud… Last author DOI 10.3389/fonc.2025.1539215↗
  12. BHLHE40 Inhibits Ferroptosis in Pancreatic Cancer Cells via Upregulating SREBF1. Last author DOI 10.1002/advs.202306298↗
  13. Gasdermin C promotes Stemness and Immune Evasion in Pancreatic Cancer via Pyroptosis-Independent Mechanism. Co-author DOI 10.1002/advs.202308990↗
  14. ATF3-induced activation of NF-κB pathway results in acquired PARP inhibitor resistance in pancreatic adenocarcinoma. Last author DOI 10.1007/s13402-023-00907-5↗
  15. Driver mutation subtypes involve with differentiated immunophenotypes influencing pancreatic cancer outcomes. Co-author DOI 10.1016/j.canlet.2024.217134↗
  16. Tumor cell-intrinsic epigenetic dysregulation shapes cancer-associated fibroblasts heterogeneity to metabolically support pancreatic cancer. Co-author DOI 10.1016/j.ccell.2024.03.005↗
  17. Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41591-023-02790-x↗
  18. Comprehensive analysis of KLF family reveals KLF6 as a promising prognostic and immune biomarker in pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s12935-024-03369-3↗
  19. Real-world implications of nonbiological factors with staging, clinical management, and prognostic prediction in pancreatic ductal adenocarcinoma. Last author DOI 10.1002/cam4.4910↗
  20. Risk factors for and prognostic values of postoperative acute kidney injury after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: A retrospective… Last author DOI 10.1002/cam4.5543↗
  21. Health-related quality of life and survival outcomes for patients with major depressive disorder and anxiety: A longitudinal study in pancreatic ductal adenoca… Last author DOI 10.1002/cam4.6577↗
  22. Pancreatic index: A prognostic factor of upfront surgery for body or tail pancreatic ductal adenocarcinoma with vascular involvement-A retrospective study. Last author DOI 10.1002/cam4.6687↗
  23. Long-term outcomes of standard versus extended lymphadenectomy in pancreatoduodenectomy for pancreatic ductal adenocarcinoma: A Chinese multi-center prospectiv… Last author DOI 10.1016/j.jare.2022.09.011↗
  24. Association between age at diabetes onset or diabetes duration and subsequent risk of pancreatic cancer: Results from a longitudinal cohort and mendelian rando… Co-author DOI 10.1016/j.lanwpc.2022.100596↗
  25. A microprotein N1DARP encoded by LINC00261 promotes Notch1 intracellular domain (N1ICD) degradation via disrupting USP10-N1ICD interaction to inhibit chemoresi… Last author DOI 10.1038/s41421-023-00592-6↗
  26. Schwann cells regulate tumor cells and cancer-associated fibroblasts in the pancreatic ductal adenocarcinoma microenvironment. Co-author DOI 10.1038/s41467-023-40314-w↗
  27. A deep-learning radiomics-based lymph node metastasis predictive model for pancreatic cancer: a diagnostic study. Last author DOI 10.1097/js9.0000000000000469↗
  28. LIPH contributes to glycolytic phenotype in pancreatic ductal adenocarcinoma by activating LPA/LPAR axis and maintaining ALDOA stability. Co-author DOI 10.1186/s12967-023-04702-6↗
  29. TP53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s12967-023-04742-y↗
  30. Retraction Note: The LINC00623/NAT10 signaling axis promotes pancreatic cancer progression by remodeling ac4C modification of mRNA. Co-author DOI 10.1186/s13045-023-01506-5↗
  31. The Impact of Additional Para-aortic Dissection During Pancreaticoduodenectomy for Resectable Pancreatic Cancer. Last author DOI 10.1245/s10434-022-12700-z↗
  32. Identification of COL12A1 as a novel diagnostic marker in pancreatic ductal adenocarcinoma by global proteome analysis Last author DOI 10.21203/rs.3.rs-3037921/v1↗
  33. [Pay attention to whole cycle management of pancreatic cancer]. First author DOI 10.3760/cma.j.cn112139-20230306-00094↗
  34. Comprehensive machine learning-generated classifier identifies pro-metastatic characteristics and predicts individual treatment in pancreatic cancer: A multice… Last author DOI 10.7150/thno.84978↗
  35. The impact of Omicron pandemic and COVID-19 vaccination on the pancreatic adenocarcinoma patients. Last author DOI 10.1002/aac2.12056↗
  36. Who could complete and benefit from the adjuvant chemotherapy regarding pancreatic ductal adenocarcinoma? A multivariate-adjusted analysis at the pre-adjuvant … Last author DOI 10.1002/cam4.4698↗
  37. The CTCF/LncRNA-PACERR complex recruits E1A binding protein p300 to induce pro-tumour macrophages in pancreatic ductal adenocarcinoma via directly regulating P… Last author DOI 10.1002/ctm2.654↗
  38. Robotic versus open pancreaticoduodenectomy with vascular resection for pancreatic ductal adenocarcinoma: surgical and oncological outcomes from pilot experien… Last author DOI 10.1007/s00423-021-02364-w↗
  39. The inhibitory effect of LINC00261 upregulation on the pancreatic cancer EMT process is mediated by KLF13 via the mTOR signaling pathway. Co-author DOI 10.1007/s12094-021-02747-x↗
  40. SRSF3-mediated regulation of N6-methyladenosine modification-related lncRNA ANRIL splicing promotes resistance of pancreatic cancer to gemcitabine. Co-author DOI 10.1016/j.celrep.2022.110813↗
  41. Clinical characteristics and surgical outcomes of resectable acinar cell carcinoma of the pancreas-propensity score matching analysis with pancreatic ductal ad… Last author DOI 10.1016/j.ejso.2021.11.135↗
  42. Postoperative hyperprogression disease of pancreatic ductal adenocarcinoma after curative resection: a retrospective cohort study. Last author DOI 10.1186/s12885-022-09719-6↗
  43. LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s13045-022-01272-w↗
  44. Worth it or not? Primary tumor resection for stage IV pancreatic cancer patients: A SEER-based analysis of 15,836 cases. Last author DOI 10.1002/cam4.4147↗
  45. Oncological outcomes of robotic-assisted versus open pancreatoduodenectomy for pancreatic ductal adenocarcinoma: a propensity score-matched analysis. Last author DOI 10.1007/s00464-020-07791-2↗
  46. Identification of copy number variation-driven molecular subtypes informative for prognosis and treatment in pancreatic adenocarcinoma of a Chinese cohort. Last author DOI 10.1016/j.ebiom.2021.103716↗
  47. Original study: The rescue staging for pancreatic ductal adenocarcinoma with inadequate examined lymph nodes. Last author DOI 10.1016/j.pan.2021.02.010↗
  48. SHCBP1 interacting with EOGT enhances O-GlcNAcylation of NOTCH1 and promotes the development of pancreatic cancer. Co-author DOI 10.1016/j.ygeno.2021.01.010↗
  49. Oncogene APOL1 promotes proliferation and inhibits apoptosis via activating NOTCH1 signaling pathway in pancreatic cancer. Last author DOI 10.1038/s41419-021-03985-1↗
  50. Higher body mass index indicated better overall survival in pancreatic ductal adenocarcinoma patients: a real-world study of 2010 patients. Last author DOI 10.1186/s12885-021-09056-0↗

Closest collaborators

The 25 strongest of 178 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaxing Deng · 42 shared papers, 2013–2026 · strength 5.44
  2. Chenghong Peng · 45 shared papers, 2012–2024 · strength 4.15
  3. Lingxi Jiang · 16 shared papers, 2020–2026 · strength 2.81
  4. Chenlei Wen · 18 shared papers, 2017–2026 · strength 2.78
  5. Hao Chen · 27 shared papers, 2013–2023 · strength 2.33
  6. Weishen Wang · 13 shared papers, 2017–2024 · strength 1.87
  7. Yizhi Cao · 10 shared papers, 2022–2025 · strength 1.69
  8. Haoda Chen · 9 shared papers, 2021–2023 · strength 1.60
  9. Shuyu Zhai · 10 shared papers, 2019–2025 · strength 1.44
  10. Siyi Zou · 10 shared papers, 2019–2025 · strength 1.43
  11. Ningzhen Fu · 9 shared papers, 2019–2023 · strength 1.37
  12. Qian Zhan · 17 shared papers, 2013–2022 · strength 1.36
  13. Yu Jiang · 8 shared papers, 2019–2026 · strength 1.31
  14. Jiabin Jin · 12 shared papers, 2013–2024 · strength 1.22
  15. Shulin Zhao · 8 shared papers, 2019–2026 · strength 1.21
  16. Pengyi Liu · 7 shared papers, 2022–2025 · strength 1.21
  17. Xiaxing Deng · 13 shared papers, 2013–2024 · strength 1.18
  18. Qian Zhan · 6 shared papers, 2021–2026 · strength 1.16
  19. Yuanchi Weng · 9 shared papers, 2015–2023 · strength 1.10
  20. Xiaomei Tang · 9 shared papers, 2017–2024 · strength 1.05
  21. Jiayu Lin · 5 shared papers, 2024–2025 · strength 0.98
  22. Kai Qin · 6 shared papers, 2021–2025 · strength 0.98
  23. Dongfeng Cheng · 9 shared papers, 2017–2024 · strength 0.98
  24. Hao Chen · 7 shared papers, 2017–2024 · strength 0.96
  25. Yang Liu · 5 shared papers, 2024–2025 · strength 0.95

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.